MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Lumos Pharma Current Ratio 2011-2026 | LUMO
Annual Current Ratio Lumos Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.05 | 5.69 | 8.85 | 10.4 | 4.01 | 14.4 | 7.96 | 4.43 | 14 | 9.21 | 16.5 | 8.01 | 4.01 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 | 3.05 | 8.5 |
Quarterly Current Ratio Lumos Pharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.39 | 1.93 | 2.64 | 3.05 | 3.9 | 4.43 | 5.69 | 5.69 | 6.89 | 7.83 | 8.19 | 8.85 | 8.63 | 8.69 | 10.8 | 10.3 | 10.3 | 10.3 | 10.3 | 3.8 | 3.8 | 3.8 | 3.8 | 8.29 | 8.29 | 8.29 | 8.29 | 6.2 | 6.2 | 6.2 | 6.2 | 3.86 | 3.86 | 3.86 | 3.86 | 9.6 | 9.6 | 9.6 | 9.6 | 6.74 | 6.74 | 6.94 | 6.94 | 5.77 | 5.77 | 5.77 | 5.77 | 2.56 | 2.56 | 2.56 | 2.56 | 4.17 | 4.17 | 4.17 | 4.17 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 | 1.39 | 6.08 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
2.68 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
2.84 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
3.81 | $ 0.88 | -1.69 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B | France |
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.1 | 1.23 % | $ 438 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
2.61 | $ 22.45 | 1.13 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
1.43 | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
2.02 | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
2.69 | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
4.13 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
3.05 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
3.05 | - | - | $ 3.74 B | USA |
 |
Cerus Corporation
CERS
|
1.41 | $ 2.03 | 5.73 % | $ 387 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
6.16 | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
8.41 | - | - | $ 231 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
2.14 | $ 13.64 | 9.82 % | $ 1.81 B |  Australia |
 |
Aeterna Zentaris
AEZS
|
1.22 | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
7.95 | $ 103.45 | 1.85 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
0.0929 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
3.86 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
2.03 | $ 1.44 | -3.36 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
2.53 | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
1.17 | $ 3.0 | 6.38 % | $ 266 M | USA |
 |
Edesa Biotech
EDSA
|
2.08 | $ 18.27 | 14.94 % | $ 58.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 3.19 | 6.69 % | $ 5.25 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
0.729 | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
0.665 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
2.41 | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
0.762 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
0.269 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |